Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Protocol: Polatuzumab-R-CHP for DLBCL
Study: Double-blind Phase III trial Untreated intermediate-risk or high-risk DLBCL Polatuzumab-R-CHP vs R-CHOP Efficacy: 2 years PFS: 76.7% vs 70.2% (HR:0.73 95% Cl 0.57-0.95 p=0.02) 2 years OS: 88.7% vs